THANK YOU FOR SUBSCRIBING
CN Bio Innovations Raises $9M to improve Drug Discovery Efficiency
CN Bio Innovations bags $9 million for enhancing the accuracy and efficiency of drug discovery.
FREMONT, CA: A leading cell culture company, CN Bio Innovations, has bagged $9 billion led by CITIC Securities Investment Co., Ltd. along with the existing investor, CN Innovations Holdings Ltd. The funds raised will support commercial development and strengthen CN Bio's position in its key market. The funds will help drive sales of the company's products and services, including the PhysioMimix™ platform. The company has also announced the relocation and expansion of its headquarters to the Cambridge Science Park, UK, including 4,000 sq. Ft. of laboratory space.
CN Bio's micro-physiological systems facilitate researchers to study drug metabolism, toxicology, and specific disease models on single- and multi-organ systems. The company's OOC technologies can replicate the micro-environments, cell-cell interactions, and biological processes, delivering efficiencies for pre-clinical drug testing with predictive human tissue-based data. CN Bio's OOC technologies can also occur in vivo, to reliably bridge the gap between conventional cell culture assays and human studies, enhancing drug discovery while reducing research and development costs. The funds raised will facilitate the company to centre the delivery of its business strategy and the organisation's commercial growth. CN Bio ensures that the company remains at the forefront of the organ-on-chip technologies field. CN Bio is thrilled to have secured this investment from both new and existing investors that will reflect both the potential of our technology, products and the unrivalled experience and capabilities of the team.
CN Bio is a leading bioengineering company specialising in single and multi-organ microphysiological systems and innovative lab technologies. The company aims to provide systems that generate clinically translatable data that can enhance the development of tomorrow's medicines. CN Bio develops human organ-on-a-chip platforms for the testing and development of therapeutics for serious human diseases.